Polymed Biopharmaceuticals

Polymed Biopharmaceuticals is a China-based biotechnology and pharmaceutical startup founded in 2018. The company specializes in developing novel protein degrader therapies for oncology and autoimmune diseases. Through the utilization of advanced technology platforms such as artificial intelligence and structural biology, Polymed aims to create first-in-class and best-in-class medicines, targeting traditionally "undruggable" proteins including IRAK4, EGFR, and KRAS G12D. The startup's lead assets, HPB-143 and HPB-092, are IND-ready for 3Q 2024. HPB-092 is a FLT3/IRAK4 dual small molecule inhibitor for patients with Acute Myeloid Leukemia and myelodysplastic disorders, while HPB-143 is an IRAK4 PROTAC intended for patients with psoriasis, atopic dermatitis, and ulcerative colitis. In addition to these, Polymed is also focused on developing KRAS G12D and EGFR PROTACs, with both IND-ready in early 2025, and a KRAS G12D Degrader Antibody Conjugate program in hit optimization. Furthermore, the company recently secured a Series A investment from 浙江科发资本管理有限公司 on 28th November 2022. With the rich pipeline of PROTACs designed for autoimmune diseases and difficult-to-target oncology, Polymed is actively seeking strategic partners to support their mission.